Literature DB >> 11931730

Herpes Simplex Virus in Children.

Richard J. Whitley1.   

Abstract

Herpes simplex virus (HSV) infections are ubiquitous. Children are infected with HSV resulting in totally asymptomatic acquisition to life-threatening disease. Therapy of HSV diseases of children can be considered according to severity and time of acquisition. Neonatal herpes simplex virus infections take one of three forms--disease localized to skin, eye, or mouth (SEM), encephalitis, or multiorgan disseminated disease. Treatment consists of intravenous (IV) administration of acyclovir. Supportive care for patients with life-threatening disease is an integral component of patient management. Mucocutaneous HSV infections in the immunocompromised host can be treated with either intravenous acyclovir or one of the orally bioavailable antiviral therapies. For hospitalized patients, therapy consists of IV acyclovir at 5 mg/kg every 8 hours for 7 to 14 days. For ambulatory patients, therapy is tailored according to age. For children less than 12 years of age, oral acyclovir is administered at a dosage of 20 mg/kg every eight hours. Although no controlled studies have been performed with valaciclovir or famciclovir, the pharmacokinetics of these medications would suggest superiority over acyclovir. Dosage recommendations have not been established for young children. For postpubertal children, dosage should mirror that of adults. Valaciclovir is administered at 500 mg twice daily. Famciclovir is administered at 125 mg three times daily. Herpes simplex keratoconjunctivitis is treated with topical triflurothymidine. Two drops are applied to the infected eye five times daily until resolved. Recurrences are managed in a similar manner. Some physicians administer oral acyclovir at the doses noted above in order to prevent frequent recurrences. Genital HSV infections can be treated with acyclovir, valaciclovir, or famciclovir. Episodic treatment of recurrent episodes is usually not necessary in childhood. Importantly, all data on the use of these compounds for these conditions have been generated in adults. Physician judgment is required for the management of recurrent herpes labialis, erythema multiforme, and herpes gladitorum. No controlled studies have been performed in children, although experience with acyclovir, valaciclovir, and famciclovir have resulted in their use.

Entities:  

Year:  2002        PMID: 11931730     DOI: 10.1007/s11940-002-0040-2

Source DB:  PubMed          Journal:  Curr Treat Options Neurol        ISSN: 1092-8480            Impact factor:   3.598


  13 in total

Review 1.  Valaciclovir: a review of its long term utility in the management of genital herpes simplex virus and cytomegalovirus infections.

Authors:  D Ormrod; L J Scott; C M Perry
Journal:  Drugs       Date:  2000-04       Impact factor: 9.546

2.  A randomized, placebo-controlled comparison of oral valacyclovir and acyclovir in immunocompetent patients with recurrent genital herpes infections. The Valaciclovir International Study Group.

Authors:  S K Tyring; J M Douglas; L Corey; S L Spruance; J Esmann
Journal:  Arch Dermatol       Date:  1998-02

Review 3.  Herpes simplex virus infections.

Authors:  R J Whitley; B Roizman
Journal:  Lancet       Date:  2001-05-12       Impact factor: 79.321

4.  Natural history of neonatal herpes simplex virus infections in the acyclovir era.

Authors:  D W Kimberlin; C Y Lin; R F Jacobs; D A Powell; L M Frenkel; W C Gruber; M Rathore; J S Bradley; P S Diaz; M Kumar; A M Arvin; K Gutierrez; M Shelton; L B Weiner; J W Sleasman; T M de Sierra; S J Soong; J Kiell; F D Lakeman; R J Whitley
Journal:  Pediatrics       Date:  2001-08       Impact factor: 7.124

5.  Safety and efficacy of high-dose intravenous acyclovir in the management of neonatal herpes simplex virus infections.

Authors:  D W Kimberlin; C Y Lin; R F Jacobs; D A Powell; L Corey; W C Gruber; M Rathore; J S Bradley; P S Diaz; M Kumar; A M Arvin; K Gutierrez; M Shelton; L B Weiner; J W Sleasman; T M de Sierra; S Weller; S J Soong; J Kiell; F D Lakeman; R J Whitley
Journal:  Pediatrics       Date:  2001-08       Impact factor: 7.124

6.  Famciclovir for the suppression of symptomatic and asymptomatic herpes simplex virus reactivation in HIV-infected persons. A double-blind, placebo-controlled trial.

Authors:  T Schacker; H L Hu; D M Koelle; J Zeh; R Saltzman; R Boon; M Shaughnessy; G Barnum; L Corey
Journal:  Ann Intern Med       Date:  1998-01-01       Impact factor: 25.391

7.  Valaciclovir for the suppression of recurrent genital herpes simplex virus infection: a large-scale dose range-finding study. International Valaciclovir HSV Study Group.

Authors:  M Reitano; S Tyring; W Lang; C Thoming; A M Worm; S Borelli; L O Chambers; J M Robinson; L Corey
Journal:  J Infect Dis       Date:  1998-09       Impact factor: 5.226

8.  Acyclovir versus vidarabine in herpes simplex encephalitis. Randomised multicentre study in consecutive Swedish patients.

Authors:  B Sköldenberg; M Forsgren; K Alestig; T Bergström; L Burman; E Dahlqvist; A Forkman; A Frydén; K Lövgren; K Norlin
Journal:  Lancet       Date:  1984-09-29       Impact factor: 79.321

9.  Predictors of morbidity and mortality in neonates with herpes simplex virus infections. The National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group.

Authors:  R Whitley; A Arvin; C Prober; L Corey; S Burchett; S Plotkin; S Starr; R Jacobs; D Powell; A Nahmias
Journal:  N Engl J Med       Date:  1991-02-14       Impact factor: 91.245

10.  A controlled trial comparing vidarabine with acyclovir in neonatal herpes simplex virus infection. Infectious Diseases Collaborative Antiviral Study Group.

Authors:  R Whitley; A Arvin; C Prober; S Burchett; L Corey; D Powell; S Plotkin; S Starr; C Alford; J Connor
Journal:  N Engl J Med       Date:  1991-02-14       Impact factor: 91.245

View more
  6 in total

Review 1.  Inborn errors of anti-viral interferon immunity in humans.

Authors:  Vanessa Sancho-Shimizu; Rebeca Perez de Diego; Emmanuelle Jouanguy; Shen-Ying Zhang; Jean-Laurent Casanova
Journal:  Curr Opin Virol       Date:  2011-12       Impact factor: 7.090

2.  Herpes simplex encephalitis in children with autosomal recessive and dominant TRIF deficiency.

Authors:  Vanessa Sancho-Shimizu; Rebeca Pérez de Diego; Lazaro Lorenzo; Rabih Halwani; Abdullah Alangari; Elisabeth Israelsson; Sylvie Fabrega; Annabelle Cardon; Jerome Maluenda; Megumi Tatematsu; Farhad Mahvelati; Melina Herman; Michael Ciancanelli; Yiqi Guo; Zobaida AlSum; Nouf Alkhamis; Abdulkarim S Al-Makadma; Ata Ghadiri; Soraya Boucherit; Sabine Plancoulaine; Capucine Picard; Flore Rozenberg; Marc Tardieu; Pierre Lebon; Emmanuelle Jouanguy; Nima Rezaei; Tsukasa Seya; Misako Matsumoto; Damien Chaussabel; Anne Puel; Shen-Ying Zhang; Laurent Abel; Saleh Al-Muhsen; Jean-Laurent Casanova
Journal:  J Clin Invest       Date:  2011-11-21       Impact factor: 14.808

3.  Case Presentation of a 23-Month-old Herpes Simplex Virus-infected Girl with Brain and Oesophageal Involvement.

Authors:  Karam-Ali Kasiri; Noushin Rostampour; Abolfazl Khoshdel
Journal:  J Clin Diagn Res       Date:  2015-05-01

Review 4.  Herpes simplex virus encephalitis of childhood: inborn errors of central nervous system cell-intrinsic immunity.

Authors:  Shen-Ying Zhang
Journal:  Hum Genet       Date:  2020-02-10       Impact factor: 4.132

Review 5.  Type I interferon dysregulation and neurological disease.

Authors:  Sarah McGlasson; Alexa Jury; Andrew Jackson; David Hunt
Journal:  Nat Rev Neurol       Date:  2015-08-25       Impact factor: 42.937

6.  Imaging findings of neonatal herpes simplex virus type 2 encephalitis.

Authors:  Arastoo Vossough; Robert A Zimmerman; Larissa T Bilaniuk; Erin M Schwartz
Journal:  Neuroradiology       Date:  2008-02-02       Impact factor: 2.995

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.